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Abstract The dose of rapid onset opioids to be given for
breakthrough cancer pain (BTcP) is controversial. Dose pro-
portional to the basal opioid regimen seem to be safe and
effective in hospital units. However, data in other less
protected settings, like home care, are lacking. The aim of this
open-label study was to assess the efficacy and safety in a
group of patients with BTcP followed at home, after giving a
dose of fentanyl buccal tablets (FBT) proportional to the
opioid basal regimen, skipping the steps for dose titration.
Consecutive patients admitted to a home care program
presenting BTcP episodes and receiving stable doses of opi-
oids for background pain were selected. Data from four con-
secutive episodes of BTcP were collected. For each episode,
patients were instructed to routinely collect changes in pain
intensity and severe adverse effects when pain got severe (T0)
and to reassess the same items 15 min after FBT, given as a
rescue medication in doses proportional to the daily opioid
doses used for background pain (T15). One hundred twenty
episodes of BTcP were recorded in 30 patients. One hundred
eight episodes were defined as successfully treated, while 12
episodes required a further administration of opioids. Pain
intensity significantly decreased at T15 (p<0.001). In 95.5
and 90.8 % of episodes treated, there was a reduction in pain
intensity of more than 33 and 50 %, respectively. No relevant
adverse effects were recorded, even in older patients. This
study suggests that FBT given in doses proportional to the
basal opioid regimen for the management of BTcP is very
effective and safe in clinical practice in the home care setting.
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Introduction
In the cancer population, breakthrough pain (BTP) is a
transitory exacerbation of pain, severe in intensity and with
a rapid onset, superimposed on an otherwise stable pain
pattern in patients treated with opioids [9, 23]. The presence
of BTP has been considered as a negative prognostic factor
and infers the quality of life of these patients [24]. The
availability of supplemental doses of opioids (rescue medi-
cation) in addition to the continuous analgesic medication is
the main treatment suggested to manage these pain flares
[10]. For years, anecdotal experience has suggested that the
starting effective dose of BTP medication must be a per-
centage of a patient's total daily opioid dose [6]. As pain
relief is usually required urgently in the last decade, new
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routes of administration have been designed to provide fast
pain relief. The use of these fentanyl delivery systems,
commonly named rapid onset opioids (ROOs), has been
shown to provide the best effective treatment in comparison
with placebo or oral morphine [5, 11]. All the trials with
ROOs, including oral transmucosal fentanyl citrate (OTFC)
and fentanyl buccal tablets (FBT), suggest to titrate the
doses of fentanyl to achieve the effective dose, as there is
no relationship between the effective fentanyl dose and a
fixed schedule opioid regimen [2, 5, 9, 27]. However, the
evidence is only indirect because it is derived from the study
design rather than on convincing comparative studies of
dosing strategies. In these regulatory studies, a substantial
proportion of patients failed the dose titration of OTFC or
FBT. Moreover, an unclear distinction between the basal
pain of mild–moderate intensity and BTP of moderate–
severe intensity makes the interpretation of data provided
by these studies difficult [13, 15]. Observations from data
pooled from trials of OTFC showed a statistically significant
relationship between the breakthrough dose and around-the-
clock dose, despite an enormous interindividual variability
in patients' dose requirements for BTP [7].
Indeed, the reasons for these findings have not been clearly
explained, considering that the presence of tolerance should
suggest a dose proportional to those used for background
analgesia for obtaining an effect. An expected tolerance to
adverse effects in patients chronically exposed to opioids has
been found, despite serum fentanyl levels as high as 6–
8 ng/mL [1]. Dose titration may make the practical use of
ROOs difficult in the daily activity, particularly at home or in
outpatients. Moreover, using different strengths of ROOs for
treating each episode may be time consuming, exceeding the
spontaneous duration for BTP which can spontaneously sub-
side, as evidenced by successful placebo-treated patients [13,
15]. Finally, many patients may be reluctant to try the dose and
avoid the use of these drugs, preferring, at the end, traditional
oral dosing of morphine [4]. In a recent survey, most patients
were using oral opioids, and only 55% of patients took rescue
medication every time they experienced BTP [6]. Thus, low
doses of ROOs, started in an attempt to titrate the doses
individually, could result in unnecessary suffering, lowering
of clinical compliance, and refusal to continue the treatment,
particularly in specific settings, such as palliative home care or
outpatient clinics, where patients should try the doses with
different attempts.
The opioid dose to be administered for BTP remains
controversial. A predictable dose could favor an easy pre-
scription resulting in a better patients' compliance. The use
of proportional doses has been shown to be safe and effec-
tive in a large number of patients in several open-label and
controlled studies [16–20]. FBT given even at high doses
proportional to the opioid doses used for background anal-
gesia was safe and effective [21]. This data was explained
by the high level of tolerance achieved by patients receiving
high doses of opioids for background analgesia. In the only
existing comparative study, this approach has been found to
be more effective than dose titration method [14].
However, data on the use of proportional dose of FBT at
home, where patients are more frequently assisted during
the course of disease, are lacking. The aim of this study was
to prospectively assess the efficacy and safety of FBT in
doses proportional to opioid doses for background analgesia
given chronically for the treatment of BTP of cancer patients
followed at home by a palliative care team.
Methods
A cohort of patients consecutively admitted to a home care
program, L'Aquila per la vita, in a period of 6 months, from
June 2011 to February 2012, was surveyed.
Patients with relevant changes in renal and liver function
as well as patients with cognitive disturbances or not col-
laborative were excluded. In addition, patients who had
unstable background analgesia or more than four episodes
of BTP/day were excluded. The criterion to define BTP was
reported in previous studies [6, 12, 14, 21]. From this
sample, patients who were receiving opioids in doses of oral
morphine equivalents equal or more than 60 mg daily were
prescribed FBT in doses proportional to opioids used for
background analgesia. For example, the minimal existing
dose, 100 μg was given to patients receiving 60 mg of oral
morphine equivalents, 200 μg was given to patients receiv-
ing 120 mg of oral morphine equivalents, 300 μg for
180 mg of oral morphine equivalents, and so on. Interme-
diate doses were rounded at the lower dose strength (exam-
ple 200 μg for 150 mg of oral morphine equivalents).
Informed consent and institutional approval were obtained.
Patients were treated according to a routine protocol.
After establishing effective around-the-clock opioid medi-
cation, according to opioid titration process, achieving a
stable analgesia, with mean pain intensity equal or less than
4/10, for two consecutive days, patients were instructed to
administer FBT at the doses calculated when their pain gets
severe, as superimposed episode of BTP occurs. Patients
and relatives were trained in using FBT, explaining the
characteristics and the way to use it.
For each episode of BTP, patients and their relatives
recorded in a specific sheet the pain intensity (numerical scale
0–10) and adverse effect intensity, using a scale from 0 to 3
(absent, slight, moderate, severe), and the occurrence of ad-
verse effects considered severe enough in intensity to require a
medical intervention just before starting the FBT dose (T0)
and 15 min after (T15). The administration of BTP opioid
medication was considered unsuccessful whenever a further
BTP medication was required in the subsequent 2 h. An on
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call service is offered for any occurrence, other than home care
routine visits planned about three times a week for both
physicians and nurses.
The principal outcome was the evaluation of the number
of patients who benefitted from FBT (at least >33 % of
decrease in pain intensity) using doses proportional to the
basal opioid regimen, within 15 min, which was considered
as a clinically meaningful time to evaluate a dose adminis-
tered as needed and the occurrence of adverse effects severe
enough in intensity to require a medical intervention. The
secondary outcome was to evaluate this aspect in older
patients, which should be considered the most susceptible
population to opioid analgesics.
Statistical analysis
One hundred twenty episodes treated with FBT at propor-
tional doses to opioid doses used for background analgesia
were deemed to be sufficient for an analysis, according to
numbers previously published in open-label studies. For
analysis, patients were divided according to the age: ≤65
and >65 years. Frequency analysis was performed using the
chi-square test. Frequency analysis was performed using the
Pearson's chi-square test and Fisher's exact test. The one-
way analysis of variance and Kruskal–Wallis statistic test
were used to compare the different parametric or nonpara-
metric variables. Data was analyzed by SPSS Software 14.0
version (SPSS, Inc., Chicago, Ill, US). All P values were
two-sided, and P values less than 0.05 were considered
statistically significant.
Results
Thirty patients were surveyed. The mean age was 68.9 years
(±13.6), and 19 (63.3 %) of them were over 65 years.
Sixteen patients were male. One hundred twenty episodes
of BTP were recorded (four for each patient). Of the 120
valuable episodes, a further BTP medication was required in
the subsequent 2 h in 12 cases (10 %). The mean dose of
FBT administered was 266.7 μg (±209.9), with 44 episodes
(36.7 %) treated with doses of FBT >200 μg. Older patients
received lower doses of opioids for background analgesia
and, as a consequence, lower doses of FBT (p<0.002)
(see Table 1).
Pain intensity significantly decreased at T15 (p<0.0005)
(see Table 1).In 117 (97.5 %) and 109 (90.8 %) episodes,
there was a reduction in pain intensity at T15 of more than
33 and 50 %, respectively. The number of episodes with a
decrease in pain intensity of more than 33 % was higher in
females (p<0.035). This data was not significant for a
decrease in pain intensity of more than 50 % (p<0.112).
Changes in pain intensity were not significant according to
the age (p=0.758 and p=0.117, respectively). No adverse
effects severe enough in intensity to require medical inter-
vention were observed. No age-related differences in ad-
verse effects intensity were found.
Discussion
The data of this study suggest that FBT, used in proportional
doses to the opioid basal regimen for the management of
BTP, is effective and safe, even at home, whereas dose
titration may be problematic, particularly in older patients.
These findings confirm preliminary observations in patients
admitted to hospital units who were receiving high doses of
opioids for background analgesia and who were effectively
treated with proportional doses of FBT, without adding risks
of occurrence of adverse effects [21]. As this approach could
not be generalized due to the characteristics of the unit, this
hypothesis was tested in another setting, like home care.
Table 1 Characteristics of patients, doses of FBT, number of BTcP episodes with a decrease in PI >33 and 50 %, respectively, and number of
episodes treated resulting in adverse effect intensity of mild–moderate intensity
All Age ≤65 years Age >65 years P value
Number of patients 30 11 19
M/F 16 14
Age 68.9 (13.6) 53.8 (7.5) 77.7 (6.6)
Evaluable episodes 120 44 76
Mean doses of FBT, μg (SD) 266.7 (209.9) 350 (235) 218 (179) 0.002
T0 pain intensity 8.7 (0.8) 9.0 (0.9) 8.6 (0.7) 0.002
T15 Pain intensity 3.0 (1.4) 3.4 (1.9) 2.8 (0.9) 0.071
Number of BTcP episodes with a decrease in PI >33 % 117 41 76 0.047a
Number of BTcP episodes with a decrease in PI >50 % 109 35 74 0.002a
Number of BTcP episodes with AE intensity 1–2 19 6 13 0.796a
a Fisher's exact test
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This observation contradicts previous indications. Data
from clinical studies of FBTshow that the patients' effective
doses, ranging from 100 to 800 μg, required a titration
process [8] because of the lack of relationship between the
effective fentanyl dose and a fixed schedule opioid regimen
[26]. Dose titration, however, may fail, especially for pa-
tients receiving high doses of opioids for background anal-
gesia, or may require prolonged periods of time to achieve
the effective dose [13, 15]. Of interest, in a survey repro-
ducing a real clinical scenario, patients receiving a mean
oral morphine daily dose of 132 mg required 800 μg of
OTFC [26], suggesting that titration process may provide
even higher doses than those expected by using proportional
doses to basal opioid regimen. Moreover, observations from
data pooled from trials of OTFC showed a statistically
significant relationship between the breakthrough dose and
around-the-clock dose, despite an enormous interindividual
variability in patients' dose requirements for BTP [9].
To affirm such a paradigm, titration method should be
compared with proportional doses in terms of efficacy and
safety, and no study has been performed with this purpose.
Data simulations have shown that doses reached after titra-
tion were quite similar to the doses calculated according the
proportional paradigm [13, 15]. Indeed, titration strategy
was recently compared with a traditional approach by using
doses proportional to basal opioid regimen. In patients receiv-
ing daily doses of oral morphine equivalents of >120 mg/day,
a significant number of patients obtained a decrease in pain
intensity of >50 % in the proportional group in comparison
with the titration group, and the need of a further rescue dose
was significantly more often reported in the titration group for
the first episode of BTP. This finding was not associated with
differences in adverse effect intensity between the two groups
[14]. In other words, proportional doses could be given more
effectively, without exposing patients to more adverse effects,
as suggested by several practical experiences with intravenous
morphine and ROOs, even at high doses and in elderly pa-
tients [16–21].
As in a previous experience, and differently from previ-
ous controlled studies of opioid titration, the selection of
BTP events to be included was strict and may allow a better
interpretation of data, as patients were trained to distinguish
acceptable fluctuations of pain. In this study, the mean
intensity of BTP was higher and clearly distinguished from
the intensity of basal pain, avoiding the influence of the gray
area of mild–moderate pain for either background analgesia
and BTP, often observed in these studies, which may infer
the quality and interpretation of data collected. Similarly, the
cut off for efficacy was more restrictive (at least a 33 %
decrease in pain intensity) in respect to a decrease of 2
points in a numerical scale. Despite the uncontrolled nature
of the study design, the strictest selection of the BTP events
to be treated offers a clinical outcome reproducible in the
daily practice. The treatment was safe and effective, and
only a minority of patients required a further treatment in the
next 2 h. Trained patients autoadministered the doses pre-
scribed, according to the proportionality between dose as
needed and background analgesics.
It could be argued that this approach could expose pa-
tients to adverse effects. However, no patient required a
medical intervention, including older patients who could
potentially be at more risk of developing adverse effects.
On the other hand, when doses of FBTwere titrated up to an
effective mean dose of 554 μg of FBT in patients who were
receiving mean doses of 240 mg/day oral morphine equiv-
alents as background analgesia, approximately half of the
patients used the maximum FBT dose of 800 μg during
maintenance treatment. Of interest, the effective doses of
FBT were consistently higher than those eventually calcu-
lated with a proportional approach (400 μg for mean doses
of 240 mg of oral morphine equivalents as ATC analgesia);
confirming that overdosing with proportional doses calcu-
lated according the opioid basal regimen is unlikely. These
patients, however, afforded titration with evident suffering
during the days before achieving the right dose [25].
This observation, explained by the level of opioid toler-
ance produced by opioid doses used for background anal-
gesia, is a protective factor against the occurrence of severe
adverse effects produced by approximately 20 % of the daily
dose, also explaining the high percentage of successfully
treated episodes. This is confirmed by the fact that intrave-
nous morphine, given as a bolus in doses proportional to
basal opioid regimen in a thousand of episodes, has been
proved to be safe and effective even at high doses and in the
elderly [16–19].
Patients treated efficaciously at home may avoid hospital
admissions and reduce social and economic resources. Sim-
plifying the treatment, while providing efficacy and safety,
is of paramount importance and could help both patients and
professionals, as many patients have concerns in titrating
doses of ROOs. In Italian surveys on attitudes of physicians
on using BTP medications, this approach is used in less than
50 % of patients [3, 22].
In conclusion, FBT given in doses proportional to the
daily doses of opioids used for background analgesia was
effective and safe as a breakthrough pain medication also in
a home care setting. This approach was safe, as no relevant
adverse effects were reported, and older patients did not
present more risks of adverse effects. These results should
be replayed to reinforce this concept and provide clear
prescription for patients.
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